Bayer, the company behind supplement brands Redoxon and Berocca, reported a “significant decline” in its nutritionals category in APAC and other major markets, but the CEO is still confident that sales would “return to healthy growth” for the full year.
It is “still too early to tell” how a post COVID-19 pandemic consumer environment will look like, says Blackmores, which has seen a mixture of gains and losses across Asia-Pacific in its latest financial results.
Infant formula producer Bubs Australia said its gross revenue has China dropped by 66 per cent, and its new Manufacturer-to-Consumer (M2C) sale channel in the country has been delayed, due to disruptions caused by China’s prolonged COVID-19 lockdowns.
China dairy giant Yili has registered record growth and increased market share in its recently-released H1FY2022 financial report, and has attributed this success to the sales of its value-added dairy products as well as its efforts in rapid new product...
ASX-listed Australian firm McPherson’s has reported almost 90 per cent annual growth in its health business in FY22, with the herbals brand Fusion – previously owned by Blackmores’ Global Therapeutics – performing particularly well.
Blackmores will beef up its local inventory for the 13 markets that it currently operates in, design new pack sizes for markets such as Thailand, and target eye health growth in China over the next year, the company’s CEO told NutraIngredients-Asia.
This round-up looks at the latest financial performance of nutraceutical and infant formula brands, including PERKii, The a2 Milk Company, Blackmores, Swisse's parent company H&H Group, and CBD specialist Elixinol.